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ABSTRACT 
Background: Despite oxygen being the commonest drug administered to critically ill 
patients we do not know which oxygen saturation (SpO2) target results in optimal survival 
outcomes in those receiving mechanical ventilation. We therefore conducted a feasibility 
randomised controlled trial in the United Kingdom (UK) to assess whether it would be 
possible to host a larger national multi-centre trial to evaluate oxygenation targets in 
mechanically ventilated patients.  
Methods: We set out to recruit 60 participants across two sites into a trial in which they were 
randomised to receive conservative oxygenation (SpO2 88-92%) or usual care (control – 
SpO2 ≥96%). The primary outcome was feasibility; factors related to safety and clinical 
outcomes were also assessed.  
Results: A total of 34 patients were recruited into the study until it was stopped due to time 
constraints. A number of key barriers to success were identified during the course of the 
study. The conservative oxygenation intervention was feasible and appeared to be safe in 
this small patient cohort and it achieved wide separation of the median time-weighted 
average (IQR) SpO2 at 91% (90-92%) in conservative oxygenation group versus 97% (96-
97%) in control group.  
Conclusion: Whilst conservative oxygenation was a feasible and safe intervention which 
achieved clear group separation in oxygenation levels, the model used in this trial will 
require alterations to improve future participant recruitment rates in the UK. 
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INTRODUCTION 
Oxygen is one of the commonest drugs used in the management of acutely unwell patients 
with respiratory failure requiring mechanical ventilation on an intensive care unit (ICU). 
Despite this, there is little available evidence or guidance on what level of arterial 
oxygenation that favours improved survival. It has been proposed that reducing arterial 
oxygenation targets (termed ‘permissive hypoxaemia’) may not only be safe but might also 
improve clinical outcomes1. A number of studies have attempted to explore the relationship 
between oxygenation and survival in critically ill patients by analysing retrospective 
datasets.2–4 The results have been varied and the conclusions must be interpreted with care 
as it is difficult to avoid confounding by treatment intention (i.e. the more unwell a patient is 
the greater likelihood of over-oxygenation) using this methodological approach. A recent 
study of hyperoxaemia in patients admitted to ICU in England used novel methods to reduce 
confounding and concluded that there was an association between hyperoxaemia and 
mortality, but did not explore the relationship between hypoxaemia and survival.5 Three 
recently published, moderate sized randomised controlled trials evaluating conservative 
oxygen therapy protocols have shown conflicting results in the critically ill. The first, a single-
centre study (n=434) comparing an oxygen saturation (SpO2) target range of 94-98% to 
usual therapy was stopped early, reporting a substantial reduction in morality in the 
intervention group.6 The second, a multi-centre study (n=1000) comparing an SpO2 target 
range of 91-96% to usual care, showed no difference in ventilator-days or survival between 
oxygenation groups.7 The third, a multi-centre study of patients with acute respiratory 
distress syndrome (ARDS) (n=205, comparing an SpO2 target range of 88-92% to ≥96%) 
was also stopped early and showed no difference in 28 day survival.8 The situation is further 
complicated by the fact that each study recruited different critically ill populations (in terms of 
severity of illness and diagnosis) and implemented different intervention and control group 
oxygenation targets. It is therefore impossible to draw any clear conclusion about 
oxygenation and survival in mechanically ventilated patients based on the current published 
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evidence except to say that there is strong historical evidence of increased mortality for 
critical care patients with very low oxygen saturation levels (SpO2 <85%) and there is 
moderate evidence of harm from marked hyperoxaemia with an arterial partial pressure of 
oxygen (PaO2) >200 mmHg or 26 kPa, equivalent to an SpO2 of 99%-100%. 
 
We therefore set out to conduct a randomised controlled trial to assess the feasibility of 
recruiting mechanically ventilated patients admitted to ICUs in England into a study 
evaluating a conservative oxygenation intervention. The purpose of the study was to 
determine criteria that could be used in a subsequent large trial to evaluate the efficacy and 





The Targeted OXYgen therapY in Critical illness (TOXYC) trial was designed according to 
the standard protocol items: recommendations for interventional trial (SPIRIT) statements.9 
Its purpose was to determine the feasibility of conducting a randomised controlled trial of a 
lower than normal (conservative) SpO2 target in adult critically ill patients requiring 
mechanical ventilation in a National Health Service (NHS) setting. The study was approved 
by the London Harrow Research Ethics Committee (reference 17/LO/1334) along with 
approval from the Health Research Authority. The trial protocol and statistical analysis plan 
were published prior to completion of participant recruitment.10 The aim was to recruit a total 
of 60 patients across two sites in England (the Royal Free Hospital, London and 
Southampton General Hospital) in 15 months; recruitment commenced in January 2018.  
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Patients 
Eligible patients were mechanically ventilated adults (18 years of age or older) within 24 
hours of an unplanned admission to ICU, who had a diagnosis of respiratory failure and 
where it was thought mechanical ventilation was expected to be required for 72 hours or 
more. Exclusions to enrolment included: admission following surgery (elective or 
unplanned), patients expected to die within 24 hours of admission to ICU, pregnant women, 
admission post-cardiac arrest, patients with chronic lung disease known (or highly 
suspected) to have baseline SpO2 in the range of the intervention arm (88-92%), admission 
post-trauma (including traumatic brain injury), known sickle cell trait or disease, ongoing 
significant haemorrhage or profound anaemia, severe peripheral vascular disease, severe 
pulmonary hypertension, other medical conditions where mild hypoxaemia would be 
contraindicated, and participation in another interventional clinical trial. Agreement to 
participate in the study was sought from the patient (if they were deemed to have capacity), 
a personal consultee, or professional consultee as appropriate.10 All patient consent and 
consultee agreement procedures adhered to the Mental Capacity Act (2005). 
 
Randomisation and treatment  
Patients were randomly assigned on a 1:1 basis (www.sealedenvelope.com) into either the 
conservative or control group, stratified by study site, using random permuted blocks of 
different sizes. In the conservative oxygen therapy group, the fractional inspired oxygen 
concentration (FIO2) was titrated to achieve an SpO2 of 88%-92%; guidance was provided to 
bedside staff but the process was not protocolised. In the control group, FIO2 was adjusted to 
maintain an SpO2 at or above 96%. The study intervention was continued until extubation, 
formation of tracheostomy, transfer to another ICU or death. Due to the nature of the 
intervention, neither the research nor the clinical teams were blinded to participant group 
allocation.  
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Participants were reviewed by the research team on a daily basis in order to assess 
compliance with the SpO2 criteria they were allocated to. Where a participant was briefly 
transferred out of ICU (e.g. investigation, or imaging) the trial was paused until they returned 
to ICU. Aside from the designated SpO2 targets, all other aspects of care remained the same 
between the intervention and control cohorts. Regular arterial blood gases were taken during 
the trial, according to local clinical guidelines. Treating clinicians were able to withdraw 
participants from the study at any point if were there any medical concerns.  
 
Protocol major amendments 
During the course of the trial, it was necessary to amend the study protocol; the major 
amendments are summarised below: 
January 2018 (NOSA001): An addition to the inclusion criteria to allow patients intubated 
whilst on ICU to be considered for enrolment within 24 hours of intubation. In the inclusion 
criteria, the expected duration of a potential participant remaining intubated was reduced 
from >72 hours to >24 hours.  
September 2018 (NOSA002): An additional level of agreement to participate in the study 
was introduced for patients who were deemed to lack the capacity to consent prior their 
current acute illness.  
February 2019 (NOSA003): The removal of the requirement to maintain an SpO2 of ≥96% 
for the participants allocated to the control group; i.e. patients allocated to the control group 
had their oxygenation managed purely by the clinical team, without any restrictions. This 
was necessary as clinicians claimed that the ≥96% target did not reflect usual practice. 
 
Outcome measures  
The primary outcome of the study was feasibility; this was defined as the ability to recruit 
patients and the rate of participant withdrawal from the study. Support for the trial from 
clinicians and the reasons for withdrawal from the study were also assessed. Feasibility of 
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recruitment was evaluated by monitoring patient screening and their subsequent agreement 
to participate, along with any withdrawal of consent during or after the study. As part of the 
feasibility assessment, adherence to the oxygenation targeting component of the study 
protocol was assessed by monitoring hourly SpO2 and any logged protocol deviations.  
 
A number of secondary outcome measures were evaluated in order to determine relevant 
endpoints for future trials and to explore potential biological mechanisms. Clinical secondary 
outcomes included ICU and hospital length of stay, survival at ICU discharge, 30 and 90 
days, and pre-defined adverse events, and change in the sequential organ failure 
assessment (SOFA) score over time. Key physiological measures were also recorded during 
the intervention period. Blood samples were taken at baseline and on days 2, 3, 5 and 10 
after recruitment to measure an array of selected of biomarkers of oxidative stress (not 
reported here).   
 
Statistical analysis 
As the primary outcome measure of this trial was feasibility, no sample size calculation was 
performed. 11 In view of a predicted mortality of approximately 30% in the study cohort we 
chose to set our sample size on the higher end of what is usually considered to be 
acceptable for a feasibility study. Data were collected from bedside charts and entered into 
an electronic clinical record form (eCRF). Data analysis was conducted blinded to specific 
group allocation. Primary and secondary outcome measures were presented using summary 
statistics. Missing data, non-compliers and withdrawals were analysed to determine if was 
bias seemed likely. Daily time-weighted mean values of FIO2, SpO2, PaO2 and arterial partial 
pressure of carbon dioxide (PaCO2) were calculated as an area under the curve using the 
area of trapezoids by multiplying the mean of the measured individual values by the duration 
of the interval, divided by the complete time of observation, then finding the sum of all values 
per participant in a 24 hour period. Similarly, for treatment time-weighted means the sum of 
all values was calculated for the total time on treatment (between 1 and 21 days). For each 
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patient, the proportion of time spent within the randomisation determined SpO2 limits were 
calculated and summarised by treatment arm. Adverse events were tabulated and grouped 
according to seriousness, severity and causality. 
 
RESULTS  
The two sites recruited a total of 34 participants between February 2018 and October 2019. 
Recruitment of patients was terminated after the 34th patient as the trial had reached the end 
of its extended recruitment window.  
 
Baseline and randomisation 
Primary respiratory diagnosis and underlying comorbidities of participants are shown in 
Tables 1 and 2 respectively; 22 (64.7%) participants were male and the median age was 66 
years (IQR 58 – 74). Key baseline respiratory measures are displayed in Table 3. 27 
(79.4%) participants were on a mandatory mode of ventilation at the start of the intervention, 
4 (11.8%) on a spontaneous mode and 4 (11.8%) on a mixed mode. Randomisation was 
balanced between the two treatment groups (17:17) and was also balanced at each site 
(10:10 at site one and 7:7 at site two). A summary of missing data is shown in the online 
supplementary information; no evidence of bias was detected.   
 
Feasibility 
The 34 participants were recruited over 622 days, an average rate of 20 participants per 
year or 1.7 per month. There were two withdrawals of consent from the study by Personal 
Consultees. Four participants were withdrawn from the study by the clinical team; reasons 
for this were i) development of a new stroke (intervention group); ii) concerns over 
excessively high FIO2 in a patient with bronchiectasis on a new CT scan (control group); iii) 
development of ischaemic colitis (intervention group); and iv) concerns over high FIO2 to 
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maintain the SpO2 target (control group). A number of factors were identified that may have 
contributed to the low recruitment rate observed in this study: 
• Method of obtaining consent from participants / agreement from consultees 
• Control group SpO2 parameters. 
• Low number of recruitment centres 
• Narrow inclusion criteria.  
 
Intervention 
The overall median (IQR) duration of intervention was 6 (3-10) days. The reason for the 
intervention being terminated in each participant (either within protocol or for other reasons) 
are summarised in Table 4. 
 
Protocol adherence 
Figure e2 in the online supplementary information shows the daily time-weighted mean 
values for SpO2 according to randomisation group. Of the 17 participants randomised to the 
conservative oxygenation group, 73.1% of daily time-weighted mean values were between 
88-92% SpO2. Of the 17 participants randomised to usual care, 75.2% of daily time-weighted 
mean values were between 96 to 100% SpO2. 
 
Oxygenation measures  
The median (IQR) time-weighted mean SpO2 for participants in the conservative oxygen 
therapy group was 91 (90-92)% and for those in the control group it was 97 (96-97)% (Table 
5). The daily time-weighted mean values for FIO2, SpO2, PaO2 and PaCO2 are shown in the 
online supplementary data (figures e1-e4 respectively). 
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Adverse events 
There was a total of 75 adverse events reported in 24 participants; the details are 
summarised in the online supplementary information (Table e2). 37 of these adverse events 
were in the conservative oxygenation group and 38 in the control group. The adverse events 
appeared well balanced between the two groups in terms of severity, causality and 
expectedness. There was a total of 23 serious adverse events; 10 in the conservative 
oxygenation group and 13 in the control group. There were 5 deaths in the conservative 
oxygenation group and 4 in the control group. There appeared to be marginally more 
respiratory and cardiovascular adverse events in the conservative oxygenation than the 
control group (65% vs. 53%, and 71% vs. 53% respectively).  
 
Clinical secondary outcomes 
Table 6 displays the key clinical secondary outcome measures by randomisation group. 
There was a trend towards higher survival and shorter ICU and hospital length of stay in the 
control group. No statistical analyses were performed as the trial was not powered to detect 
a difference in these secondary measures.  
 
DISCUSSION 
Whilst a number of moderate sized RCTs have set out to address the issue of determining 
the optimal oxygenation targets in critically ill patients, none of them have been conducted in 
the setting of the UK NHS, and to date, no clear answer has emerged. For these reasons, 
we undertook a study to assess the feasibility of conducting a trial in which mechanically 
ventilated NHS patients were enrolled and randomised to assess a conservative approach to 
oxygenation (SpO2 88-92%). The primary outcome of this trial was an assessment of 
feasibility which included the ability to recruit participants, deliver the intervention, retain 
patients in the study and collect meaningful data.  
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Adequate recruitment of participants is key to the success of any trial and is determined by 
factors such the suitability of inclusion criteria for the population to be screened, willingness 
of patients (or their next of kin) to enrol, the intervention (including an understanding of its 
potential benefits and harms) and the method and duration of data collection / sample 
collection. Recruitment to this trial was considerably slower than was predicted, which led to 
the study being stopped before reaching the target number of participants. The original plan 
was to recruit 60 patients at two centres in 15 months; this equates to 4 patients per month. 
A total of 34 patients were recruited to the study at a mean rate of 1.7 per month. 
Recruitment rate was reviewed regularly during the study, both at Trial Management Group 
(TMG) and Trial Steering Committee (TSC) meetings. The factors highlighted to have 
contributed to the low recruitment rate would need to be fully addressed to improve 
recruitment in a future trial: 
1. Method of consenting participants. The process of agreement to enter this trial was to 
seek approval from a patient’s next of kin, referred to as a personal consultee. The 
reason for this is that most patients fulfilling the inclusion criteria for the trial lacked 
capacity due to their severity of illness and / or level of sedation. Discussing research 
with a patient’s relatives soon after the patient has been admitted to an ICU with a life-
threatening condition can be extremely distressing for some families. Many are unable to 
take on board complex information whilst under such considerable stress. For this 
reason, many families decline or ask for additional time to consider the enrolment 
process, which would place the patient outside of the time-frame of recruitment for the 
study. Many trials of emergency therapy, especially in ICU, now use a model of deferred 
consent in which the patient is recruited into the trial as soon as inclusion criteria are met 
and their family are informed at a later point in time. This approach was successful for a 
trial of conservative oxygenation in critically ill children in the UK12 and in the recent ICU-
ROX trial conducted in New Zealand and Australia.7  
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2. Control (comparator) group parameters. Whilst precisely defining an intervention is 
crucial, many trials fail to deliver a meaningful message because the comparator group 
did not represent usual or common practice. The efficacy of an intervention can be both 
under and over exaggerated by creating an unrealistic comparator. When this trial was 
conceived in 2015, it was common for oxygen to be titrated to achieve normal or 
supranormal levels of arterial oxygenation in mechanically ventilated patients.4, 13 During 
the course of the trial, increasing awareness of the potential harm that may be caused by 
hyperoxaemia in critically ill patients14 led some clinicians at the two recruitment centres 
to feel uneasy enrolling patients into a trial in which the control group must have an SpO2 
of ≥ 96%. This was felt to have a detriment impact on patient enrolment. On advice from 
the TSC we therefore removed the SpO2 ≥ 96% criteria from the control group of the 
study, allowing clinicians to select whatever oxygenation target they thought appropriate. 
Of note, a recent analysis of 29,657 index ICU patient episodes conducted from 2014-19 
in England demonstrated an overall average SpO2 of 96.2%15 which was similar to the 
average SpO2 of 97% in the control group in the present study.   
 
3. Low number of recruitment sites. Due to constrains of funding we were only able to 
register two recruitment sites for this feasibility study. One of the sites encountered 
logistical issues during the recruitment period resulting in effectively only one site being 
able to actively recruit for a number of months. With hindsight, this feasibility study 
should have been designed with more recruitment centres. Whilst two additional 
recruitment sites were identified during the study, the process of adding these sites to 
the study was excessively lengthy and eventually both sites took the decision not to join 
the study.  
 
4. Inclusion and exclusion criteria. As a feasibility trial, and the first time that 
conservative oxygenation had been used as an intervention in mechanically ventilated 
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patients in the NHS, this was a cautious and restrictive study design. We sought only to 
recruit patients with a primary diagnosis of acute respiratory failure and opted for a long 
list of exclusion criteria. The reasons for this were to limit the trial to those in whom 
hypoxaemia was likely to be a part of their presenting complaint (respiratory failure) and 
to avoid any unnecessary exposure to potential harm in groups of patients that may be 
susceptible to moderate hypoxaemia (e.g. haemorrhage or anaemia). One of the 
excluded cohorts was patients who had been admitted to ICU following a cardiac arrest. 
The reason for this was that it was hypothesised that hypoxaemia may reduce cerebral 
oxygenation and lead to harm. However, sub-group analysis of data from the ICU-ROX 
trial and a subsequent meta-analysis show that this hypothesis may have been 
incorrect.7, 16 
 
In summary, a future trial of conservative oxygenation in an NHS setting should consider 
broad inclusion and minimal exclusion criteria, an unrestricted usual care comparator group, 
a deferred consent model for enrolment and a large number of simultaneously recruiting 
sites.  
 
The intervention was halted prematurely (outside of a protocolised reason to end the 
intervention period) in a total of 10 (29.4%) patients. The commonest reason (40%) was a 
clinician withdrawing the patient from the study. In these cases, clinicians expressed 
concerns regarding oxygenation in both the conservative oxygenation (20% of clinician 
withdrawals) and control (20%) groups. This was an unexpected finding and efforts to rectify 
concerns in the control arm of the study led to the protocol change outlined above. 
Adherence to the designated SpO2 targets was comparable between the two groups (Figure 
e2) and achieved for the majority of the time. Separation of oxygenation measures between 
the randomisation groups was good, as highlighted in Table 5 and Figures e1-4. There was 
a difference of 3.2 kPa between median PaO2 values in the conservative and usual practice 
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groups (Table 7), which compares to 1.6 kPa in the recently published ICU-ROX trial.7 Of 
note, this was achieved despite only a small difference between median FIO2 in the two 
groups of our study (0.35 versus 0.37 in conservative and usual care groups respectively) 
(Table 5).  
 
This study was not powered to formally assess the safety and efficacy of the intervention as 
compared to practice in the control group. The values in Table 6 show a trend toward better 
survival in the control group, accompanied by a shorter ICU length of stay; along with a 
similar pattern for hospital survival and length of stay. Whilst it is impossible to place any 
meaning to these findings due to the design of this study, it is noteworthy that a recent trial 
of conservative oxygen therapy (target SpO2 88-92% in patients with ARDS reported a 28 
day mortality of 34.3% in the conservative oxygen group and 26.5% in the ‘liberal’ oxygen 
group (SpO2 ≥96%), a difference of 7.8 % (95% confidence interval -4.8 to 20.6).8 The trial 
was stopped early by the data and safety monitoring board because of safety concerns and 
a low likelihood of a significant difference between the two groups for the primary outcome.  
 
Many of the limitations of this study design have been outlined above. The purpose of the 
study was to determine whether patients could be enrolled into a trial that delivered an 
intervention to generate separation in terms of delivered oxygen concentration and arterial 
oxygenation. An additional limitation was what appeared to be a high degree of missing data 
in this study (Table e1 in the online supplementary information). Many of the missing figures 
were due to these data not being part of routine ICU data capture at the frequency stated in 
the CRF. For example, the high degree of missing values for arterial blood gases is because 
they are not routinely taken hourly; they tend to be taken 4-6 hourly, at the discretion of the 
clinical team. Finally, the administration of oxygen therapy cannot be delivered in a blinded 
manner, therefore it is possible that knowledge of group allocation could have led to bias in 
the study results.  




Whilst this trial was feasible in an NHS setting, it would require a number of fundamental 
alterations to the design of the study in order for it to be successful on a larger scale. There 
remains no answer to the question of whether a conservative oxygen intervention is 
beneficial to mechanically ventilated ICU patients, nor the precise SpO2 target for the 
intervention. The methodology of this feasibility study delivered a clear separation of SpO2 
and PaO2 between the intervention group and the control groups. 
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TABLES 
Table 1. Primary respiratory diagnosis of study participants at enrolment  
Pneumonia 27 (79.4%) 
Pulmonary oedema 3 (8.8%) 
Pleural effusion 3 (8.8%) 
Pneumonitis 1 (2.9%) 
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Table 2. Underling comorbidities of participants at enrolment 
Cardiovascular disease 19 (55.9%) 
Chronic lung disease 4 (11.8%) 
Cancer 4 (11.8%) 
Chronic kidney disease 3 (8.8%) 
Chronic liver disease 7 (20.6%) 
Immunosuppressed 5 (14.7%) 
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Table 3. Baseline respiratory characteristics of all participants 
 
median (IQR) 
PaO2 (kPa) 11.4 (10.0-13.1) 
PaCO2 (kPa) 5.3 (5.0-6.2) 
SpO2 (%) 95 (93-97) 
FIO2 0.43 (0.35-0.50) 
Tidal volume (ml) 522 (455-620) 
Mean inspiratory pressure (cmH20) 11 (10-13) 
Peak inspiratory pressure (cmH20) 25 (20-29)  
Positive end expiratory pressure (PEEP) 
(cmH2O) 
10 (8-12) 
Total SOFA Score 11 (9-13) 
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Table 4. Reasons for terminating the intervention  




Relatives withdrew patient from the study 2 
Clinicians withdrew patient from study 4 
Withdrawal of treatment in ICU initiated  3 
Transfer of patient to another hospital** 1 
* predetermined stop points for the intervention.  
** specified in the protocol as no ethics permission in receiving hospital.  
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Table 5. Treatment time-weighted averages [median (IQR)] 
Randomised 
treatment 





91 (90-92) 8.6 (8.0-9.4) 5.6 (5.1-6.2) 
Control group 0.37 (0.30-
0.52) 
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Table 6. A summary of key clinical outcomes by randomisation group 






Final ICU outcome [Alive] (%) 11 (64.7) 12 (70.6) 
ICU length of stay (hours) [median 
(IQR)] 
362 (244-787) 303 (194-601) 
Final hospital outcome [Alive] (%) 10 (58.8) 12 (70.6) 
Hospital length of stay (days) [median 
(IQR)] 
43 (21-66) 25 (18-39) 
Survival at 30 days [Alive] (%)* 11 (68.8) 12 (70.6) 
Survival at 90 days [Alive] (%)** 9 (56.2)  11 (68.8) 
 
* Information is missing from one participant in the conservative group 
** Information is missing from one participant in the conservative group and one in the 
control group.  
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Table 7. Separation of intervention groups in terms of arterial partial pressure of oxygen for 











This study (Martin 
et al.) 
Conservative O2 88-92% 8.6  
3.2 Control Usual care 11.8 
 
Girardis et al.6 
Conservative O2 94-98% 11.6  
2.0 Control Usual care 13.6 
 
Mackle et al.7 
Conservative O2 91-96% 10.9*  
1.6 Control ≥91% 12.5* 
 
Barrot et al.8 
Conservative O2 88-92% 9.3*  
4.6 Control ≥96% 13.9* 
 
* converted to kPa if expressed as mmHg 
 
Median PaO2 and group separation in controlled trials of conservative oxygen therapy in 
Critical Care settings. The values for means for Mackle et al and Barrot et al’s studies were 
estimated from graphs in supplemental appendices provided with the manuscripts.  
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ONLINE SUPPLEMENTARY INFORMATION  
 





 01.0 Registration  0 0 
 02.0 Diagnosis  0 0 
 03.0 Medical History  0 0 
 04.1 Eligibility & Randomisation (Sealed Envelope) SE 0 0 
 04.2 Randomisation  0 0 
 05.1 & 05.2 APACHE II  





 06.1 & 06.2 SOFA 0 0 
 07.1 & 07.2 & 07.3 Clinical Data I (Pre–Intervention)  
PaO2 (kPa) 
PaCO2 (kPa) 
Mean inspiratory pressure (cmH20) 
Peak inspiratory pressure (cmH20) 
Positive End Expiratory Pressure (PEEP) (cmH2O) 
Mean airway pressure (cmH2O) 
Richmond Agitation Sedation Scale (RASS) Score 
Alanine transaminase (ALT) (IU/L) 
Aspartate transaminase (AST) (IU/L) 
Prothrombin time (PT) (sec) 











































 09.1 to 09.4 Clinical Data III (Bloods & Clinical 
Assessment)  
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Platelet count (x10 /L) 
Total Bilirubin (µmol/L) 
Lactate (mmol/L) 
pH 
Alanine aminotransferase (ALT) (IU/L) 
Aminotransferase (AST) (IU/L) 
Prothrombin time (PT) (sec) 
Activated Partial Thromboplastin Time (APTT) (sec) 
Mean arterial pressure (MAP) (mmHg) 
Heart rate (beats per minute) 
Number of packed red cells in the last 24 hours 
Mode of mechanical ventilation 
Total respiratory rate (breaths per minute) 
Tidal volume (ml) 
Mean inspiratory pressure (cmH20) 
Peak inspiratory pressure (cmH20) 
Positive End Expiratory Pressure (PEEP) (cmH2O) 
Mean airway pressure (cmH2O) 
Richmond Agitation Sedation Scale (RASS) Score 
Glasgow Coma Scale (Score) 









































 10.0 Blood sampling (Oxidative Stress)  Day 2, 3, 5, 10 





 11.0 End of intervention & Participant consent  0 0 
 12.0 Survival Outcome  





 13.0 Adverse Events (AE)  





 14.0 Principal Investigator eSignoff 








Table e2. Summary of adverse event data by randomised treatment 
 
Martin et al. TOXYC trial manuscript  18-12-2020 
 26 
Adverse event data 



































Requirement for inotropic support 
Anaemia 
Low platelet count 
High white blood cell count 
Acute kidney injury 
Requirement for renal support 
Diarrhoea 
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Table e3. Summary of protocol deviations 
There were 22 protocol deviations in 15 participants: 
• 19 procedure /assessment not done 
• 1 procedure / assessment done, but out of window 
• 2 others: 
o “Atrial fibrillation episode at 03:30 am, decision made to increase FIO2 to 40% 
by clinical team. Saturations were at 92%, PaO2 at 9.1 kPa. Research team 
not informed. Saturations subsequently increased above target range. This 
was not followed for 3.5 hours. ICU research team discovered event at 07:00. 
DM (PI) present and informed of the situation, he discussed with the night 
team. Protocol recommenced.” 
o “Bloods taken at 11:11 am on 14/05/18 - in the study Day 2 window. Due to 
confusion over study days, the processed bloods were stored in aliquots 
labelled for Day 3 samples.” 
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Figure e1  
Daily time-weighted mean values for fractional inspired oxygen concentration in the 
conservative oxygen therapy and control groups 
 
 
The bottom and top edges of the box indicate the intra-quartile range (IQR). The line inside 
the box indicates the median value. The marker inside the box indicates the mean value. 
The whiskers that extend from each box indicate the range of values that are outside of the 
intra-quartile range. However, they are close enough not to be considered outliers (a 
distance less than or equal to 1.5*IQR). Outliers are observations that are more extreme 
than the upper and lower whiskers (plus minus 1.5 IQR) 
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Figure e2  
Daily time-weighted mean values for oxygen saturation in the conservative oxygen therapy 
and control groups.  
 
 
The bottom and top edges of the box indicate the intra-quartile range (IQR). The line inside 
the box indicates the median value. The marker inside the box indicates the mean value. 
The whiskers that extend from each box indicate the range of values that are outside of the 
intra-quartile range. However, they are close enough not to be considered outliers (a 
distance less than or equal to 1.5*IQR). Outliers are observations that are more extreme 
than the upper and lower whiskers (plus minus 1.5 IQR). Horizontal lines show the protocol-
specified minimum and maximum SpO2 for each randomised arm (blue is intervention and 
green is control). 
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Figure e3  
Daily time-weighted mean values for arterial partial pressure of oxygen in the conservative 
oxygen therapy and control groups 
 
 
The bottom and top edges of the box indicate the intra-quartile range (IQR). The line inside 
the box indicates the median value. The marker inside the box indicates the mean value. 
The whiskers that extend from each box indicate the range of values that are outside of the 
intra-quartile range. However, they are close enough not to be considered outliers (a 
distance less than or equal to 1.5*IQR). Outliers are observations that are more extreme 
than the upper and lower whiskers (plus minus 1.5 IQR) 
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Figure e4.  
Daily time-weighted mean values for arterial partial pressure of carbon dioxide in the 
conservative oxygen therapy and control groups 
 
 
The bottom and top edges of the box indicate the intra-quartile range (IQR). The line inside 
the box indicates the median value. The marker inside the box indicates the mean value. 
The whiskers that extend from each box indicate the range of values that are outside of the 
intra-quartile range. However, they are close enough not to be considered outliers (a 
distance less than or equal to 1.5*IQR). Outliers are observations that are more extreme 
than the upper and lower whiskers (plus minus 1.5 IQR) 
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